nach oben

Erschienen in:

31.07.2021 | Original Article

Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study

verfasst von: Sriram Yennurajalingam, Karen Basen-Engquist, James M. Reuben, Bryan M. Fellman, Sanjay Shete, Rama Maddi, Janet L. Williams, Rony Dev, David Hui, Eduardo Bruera

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer-related fatigue (CRF) is the most frequent and debilitating symptom in patients with advanced cancer. There are limited effective treatments for CRF. The objective of this prospective longitudinal study was to evaluate the change in CRF at Day 43 after treatment with combination therapy of oral Anamorelin 100 mg daily with physical activity and nutrition counseling.

Methods

In this study, patients with CRF [≤ 34 Functional Assessment of Chronic Illness Therapy-Fatigue subscales(FACIT-F)] received Anamorelin 100 mg orally daily with standardized physical activity and nutrition counseling for 43 days. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Anorexia Cachexia(FAACT-ACS), Multidimensional Fatigue Symptom Inventory-Short Form(MFSI-SF), Patient-Reported Outcomes Measurement Information System(PROMIS-Fatigue), body composition, and physical performance tests were assessed at baseline, Day 15, 29, and 43. Frequency and type of side effects were determined by NCI CTAE 4.0.(NCT03035409).

Results

28/45 (62%) of patients dosed were evaluable at Day 43. The mean, SD for FACIT-F subscale improvement from baseline was 4.89 (± 13.07), P = .058, MFSI-SF (G) − 3.46 (± 6.86), P = 0.013, PROMIS-fatigue − 4.14 (± 7.88), P = 0.010, FAACT ACS 3.48 (± 8.13), P = 0.035. Godin Liesure-Time physical activity questionnaire 7.41 (± 16.50), P = 0.038. Weight (kg) 1.81 (± 2.63), P = 0.005, and Lean Body Mass 1.54 (± 1.85), P = 0.001, IGF-1 36.50 (± 48.76), P = 0.015. There was no significant improvement in physical performance outcomes. No adverse events > grade 3 related to the study drug were reported.

Conclusion

The use of the combination therapy was associated with improvement of CRF (FACIT-F fatigue, PROMIS-fatigue, MFSI-SF-general), activity (Godin-leisure time), anorexia (FAACT), body composition, and IGF-1 levels. Further studies using combination therapy for CRF are justified.

Nur mit Berechtigung zugänglich

Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey Cancer Fatigue Forum. Annal oncology: official journal of the European Society for Medical Oncology 11(8):971–975. https://doi.org/10.1023/a:1008318932641CrossRef

Yennurajalingam S, Urbauer DL, Casper KLB, Reyes-Gibby CC, Chacko R, Poulter V (2011) Impact of a palliative care consultation team on cancer-related symptoms in advanced cancer patients referred to an outpatient supportive care clinic. J Pain Symptom Manage 41(1):49–56. https://doi.org/10.1016/j.jpainsymman.2010.03.017CrossRefPubMed

Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J (2004) Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 32:40–50. https://doi.org/10.1093/jncimonographs/lgh027CrossRef

Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34(1):94–104. https://doi.org/10.1016/j.jpainsymman.2006.10.015CrossRefPubMed

Bower JE (2014) Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 11(10):597–609. https://doi.org/10.1038/nrclinonc.2014.127CrossRefPubMedPubMedCentral

Charalambous A, Kouta C (2016) Cancer related fatigue and quality of life in patients with advanced prostate cancer undergoing chemotherapy. Biomed Res Int 2016:3989286. https://doi.org/10.1155/2016/3989286CrossRefPubMedPubMedCentral

Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12:4–10. https://doi.org/10.1634/theoncologist.12-S1-4CrossRefPubMed

Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C (2015) Cancer-related fatigue, Version 2.2015. J Natl Compr Canc Netw 13(8):1012–1039. https://doi.org/10.6004/jnccn.2015.0122CrossRefPubMedPubMedCentral

Courneya KS, McKenzie DC, Reid RD, Mackey JR, Gelmon K, Friedenreich CM, Ladha AB, Proulx C, Lane K, Vallance JK, Segal RJ (2008) Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. Ann Behav Med 35(1):116–122. https://doi.org/10.1007/s12160-007-9009-4CrossRefPubMed

10.

Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, Mohr D, Palesh OG, Peppone LJ, Piper BF, Scarpato J, Smith T, Sprod LK, Miller SM (2017) Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 3(7):961–968. https://doi.org/10.1001/jamaoncol.2016.6914CrossRefPubMedPubMedCentral

11.

Puetz TW, Herring MP (2012) Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. Am J Prev Med 43(2):e1-24. https://doi.org/10.1016/j.amepre.2012.04.027CrossRefPubMed

12.

Yennurajalingam S, Bruera E (2014) Role of corticosteroids for fatigue in advanced incurable cancer: is it a “wonder drug” or “deal with the devil.” Curr Opin Support Palliat Care 8(4):346–351. https://doi.org/10.1097/spc.0000000000000093CrossRefPubMed

13.

Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31(25):3076–3082. https://doi.org/10.1200/JCO.2012.44.4661CrossRefPubMed

14.

Garcia JM, Friend J, Allen S (2013) Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21(1):129–137. https://doi.org/10.1007/s00520-012-1500-1CrossRefPubMed

15.

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K (2018) Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124(3):606–616. https://doi.org/10.1002/cncr.31128CrossRefPubMed

16.

Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17(4):519–531. https://doi.org/10.1016/s1470-2045(15)00558-6CrossRefPubMed

17.

Zhang H, Garcia JM (2015) Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother 16(8):1245–1253. https://doi.org/10.1517/14656566.2015.1041500CrossRefPubMedPubMedCentral

18.

Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC (2017) ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Annals of oncology: official journal of the European Society for Medical Oncology 28(8):1949–1956. https://doi.org/10.1093/annonc/mdx192CrossRef

19.

Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42(7):1409–1426. https://doi.org/10.1249/MSS.0b013e3181e0c112CrossRefPubMed

20.

Simmonds MJ (2002) Physical function in patients with cancer: psychometric characteristics and clinical usefulness of a physical performance test battery. J Pain Symptom Manage 24(4):404–414. https://doi.org/10.1016/s0885-3924(02)00502-xCrossRefPubMed

21.

Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO (1990) A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 51(2):241–247. https://doi.org/10.1093/ajcn/51.2.241CrossRefPubMed

22.

Molfino A, Gioia G, Rossi Fanelli F, Muscaritoli M (2013) Beta-hydroxy-beta-methylbutyrate supplementation in health and disease: a systematic review of randomized trials. Amino Acids 45(6):1273–1292. https://doi.org/10.1007/s00726-013-1592-zCrossRefPubMed

23.

Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24(6):547–561. https://doi.org/10.1016/s0885-3924(02)00529-8CrossRefPubMed

24.

Stein KD, Jacobsen PB, Blanchard CM, Thors C (2004) Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 27(1):14–23. https://doi.org/10.1016/j.jpainsymman.2003.06.003CrossRefPubMedPubMedCentral

25.

Rothrock NE, Hays RD, Spritzer K, Yount SE, Riley W, Cella D (2010) Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol 63(11):1195–1204. https://doi.org/10.1016/j.jclinepi.2010.04.012CrossRefPubMedPubMedCentral

26.

Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT (2000) Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation 9(10):1137–1146. https://doi.org/10.1023/a:1016670403148CrossRef

27.

Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9CrossRefPubMed

28.

Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213. https://doi.org/10.1016/0165-1781(89)90047-4CrossRefPubMed

29.

Jones CJ, Rikli RE, Beam WC (1999) A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport 70(2):113–119. https://doi.org/10.1080/02701367.1999.10608028CrossRefPubMed

30.

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test (2002). Am J Respir Crit Care Med 166(1):111–117. https://doi.org/10.1164/ajrccm.166.1.at1102

31.

Godin G, Shephard RJ (1985) A simple method to assess exercise behavior in the community. Canadian journal of applied sport sciences Journal canadien des sciences appliquees au sport 10(3):141–146PubMed

32.

Alkahtani SA (2017) A cross-sectional study on sarcopenia using different methods: reference values for healthy Saudi young men. BMC Musculoskelet Disord 18(1):119. https://doi.org/10.1186/s12891-017-1483-7CrossRefPubMedPubMedCentral

33.

Buckinx F, Reginster JY, Dardenne N, Croisiser JL, Kaux JF, Beaudart C, Slomian J, Bruyère O (2015) Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptiometry: a cross-sectional study. BMC Musculoskelet Disord 16:60. https://doi.org/10.1186/s12891-015-0510-9CrossRefPubMedPubMedCentral

34.

Fearon KC, Glass DJ, Guttridge DC (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16(2):153–166. https://doi.org/10.1016/j.cmet.2012.06.011CrossRefPubMed

35.

Brown DJ, McMillan DC, Milroy R (2005) The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 103(2):377–382. https://doi.org/10.1002/cncr.20777CrossRefPubMed

36.

Yennurajalingam S, Tayjasanant S, Balachandran D, Padhye NS, Williams JL, Liu DD, Frisbee-Hume S, Bruera E (2016) Association between daytime activity, fatigue, sleep, anxiety, depression, and symptom burden in advanced cancer patients: a preliminary report. J Palliat Med 19(8):849–856. https://doi.org/10.1089/jpm.2015.0276CrossRefPubMedPubMedCentral

37.

Bruera E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G, Baracos V (2003) Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21(1):129–134. https://doi.org/10.1200/jco.2003.01.101CrossRef

38.

Bruera E, Ernst S, Hagen N, Spachynski K, Belzile M, Hanson J, Summers N, Brown B, Dulude H, Gallant G (1998) Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer prevention & control CPC Prevention & controle en cancerologie PCC 2(2):74–78

39.

Saligan LN, Olson K, Filler K, Larkin D, Cramp F, Yennurajalingam S, Escalante CP, del Giglio A, Kober KM, Kamath J, Palesh O, Mustian K (2015) The biology of cancer-related fatigue: a review of the literature. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 23(8):2461–2478. https://doi.org/10.1007/s00520-015-2763-0CrossRef

40.

de la Cruz M, Hui D, Parsons HA, Bruera E (2010) Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer 116(3):766–774. https://doi.org/10.1002/cncr.24751CrossRefPubMed

Titel: Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study
verfasst von: Sriram Yennurajalingam
Karen Basen-Engquist
James M. Reuben
Bryan M. Fellman
Sanjay Shete
Rama Maddi
Janet L. Williams
Rony Dev
David Hui
Eduardo Bruera
Publikationsdatum: 31.07.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 1/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06463-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study